11月25日 - ** 药物开发商 Lixte Biotechnology LIXT.O股价盘前上涨 7% 至 4.78 美元
** 公司称已收购欧洲 Liora Technologies 公司，该公司开发用于癌症治疗的质子治疗系统
** Liora 的旗舰产品 "LiGHT 系统 "旨在以更低的成本和更少的疗程提供高精度质子治疗 - LIXT
** 骊住称系统已在英国 STFC 达雷斯伯里实验室安装；计划创建癌症治疗卓越中心
** 交易将合作范围从癌症药物扩展到放射治疗；补充其癌症疗法 LB-100 治疗卵巢癌和结肠癌的试验
** 质子疗法是一种利用质子而不是 X 射线靶向肿瘤的癌症放射治疗方法
** 截至上次收盘，股价年累计上涨约 120
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.